Drug Profile
Research programme: enzyme replacement therapy - Chiesi Farmaceutici
Alternative Names: Agazym; Aspartylglucosaminuria; Galaczym; Recombinant lysosomal galactocerebrosidase; rhAGA; rhGALC; ZA 011Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Zymenex A/S
- Developer Chiesi Farmaceutici
- Class Enzymes; Recombinant proteins
- Mechanism of Action Amidohydrolase replacements; Galactosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders; Unspecified
- Discontinued Globoid cell leukodystrophy; Lysosomal storage diseases
Most Recent Events
- 28 Feb 2023 Discontinued - Preclinical for Globoid cell leukodystrophy in Denmark (unspecified route) (Chiesi pipeline, February 2023)
- 28 Feb 2023 Discontinued for Lysosomal storage diseases in Denmark (unspecified route) (Chiesi pipeline, February 2023)
- 28 Feb 2023 Preclinical trials in CNS disorders in Italy (unspecified route) (Chiesi pipeline, February 2023)